ホームページ PI3K/Akt/mTOR PI3K inhibitor - Apoptosis related activator Buparlisib (BKM120) For research use only.

Buparlisib (BKM120)

別名：NVP-BKM120

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

Buparlisib (BKM120)化学構造

CAS No. 944396-07-0

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 40800 国内在庫あり
JPY 25500 国内在庫あり
JPY 48000 国内在庫あり
JPY 145500 国内在庫あり
JPY 595500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール：[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例（260）

製品安全説明書

現在のバッチを見る： 純度： 99.94%
99.94

Buparlisib (BKM120)関連製品

シグナル伝達経路

PI3K Signaling Pathways

PI3Kシグナル伝達経路

PI3K阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
MDA-MB-361 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
ZR-75-30 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
EFM-19 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC1500 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
MDA-MB-134 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
MDA-MB-175 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
LNZ308 Function Assay 5 μM 24 h Inhibits phosphorylation of AKT 24741074
LN18 Function Assay 5 μM 24 h Inhibits phosphorylation of AKT 24741074
U87 Growth Inhibition Assay 20 μM 72 h IC50<5 μM 24741074
T98G Growth Inhibition Assay 20 μM 72 h IC50<5 μM 24741074
LNZ308 Growth Inhibition Assay 20 μM 72 h IC50<5 μM 24741074
LN229 Growth Inhibition Assay 20 μM 72 h IC50<5 μM 24741074
LN18 Growth Inhibition Assay 20 μM 72 h IC50<5 μM 24741074
SJSA-1 Growth Inhibition Assay 50 μM 48 h Inhibits cell viability 24727660
MG-63 Growth Inhibition Assay 50 μM 48 h Inhibits cell viability 24727660
Saos-2 Growth Inhibition Assay 50 μM 48 h Inhibits cell viability 24727660
SJSA-1 Function Assay 50 μM 48 h Inhibits matrix metalloproteinase-2 expression 24727660
MG-63 Function Assay 50 μM 48 h Inhibits matrix metalloproteinase-2 expression 24727660
Saos-2 Function Assay 50 μM 48 h Inhibits matrix metalloproteinase-2 expression 24727660
SJSA-1 Function Assay 50 μM 48 h Inhibits cell invasion 24727660
MG-63 Function Assay 50 μM 48 h Inhibits cell invasion 24727660
Saos-2 Function Assay 50 μM 48 h Inhibits cell invasion 24727660
U87 Function Assay 5 μM 24 h Reduces oxygen consumption 24631147
HCT116 Function Assay 5 μM 24 h Reduces oxygen consumption 24631147
EMT6 Function Assay 5 μM 24 h Reduces oxygen consumption 24631147
FaDu Function Assay 5 μM 24 h Reduces oxygen consumption 24631147
GBM Apoptosis Assay 2μM 48h induced higher levels of apoptosis, and decreased cell viability 24500492
BON Apoptosis Assay 1-5μM 24h increases apoptosis 24443523
BON Growth Inhibition Assay 1-5μM 72h decreases cell proliferation 24443523
H1975 Apoptosis Assay 2μM 24h increases apoptosis rate significantly 24337846
H1975 Growth Inhibition Assay 0.3-9.6μM 72h IC50=1.385μM 24337846
T-ALL Apoptosis Assay between 1.4 and 5.3 mM at 24h and 0.9 and 5.5 mM at 48h in different cell line 24 or 48h affects the PI3K pathway in T-ALL cell lines 24310736
BCR-ABL Growth Inhibition Assay 0.25-10μM 4d significantly inhibit cell proliferation 24244612
LC-1/SQSF Function Assay 3μM 24h decrease NRF2 protein level 23980093
Primary CLL cells Cytotoxic Assay 2μM 24h induces cell cytotoxicity 23850807
Primary CLL cells Kinase Assay 2μM 30min decreased PI3K activity 23850807
Primary CLL cells Apoptosis Assay 1-10μM 48h induces apoptosis in CLL cells independent of prognostic markers 23850807
human NSCLC cell lines Apoptosis Assay 0.125-4μM 24h IC50s ranges from 0.4-2μM 23562472
Huh7 Kinase Assay 1μM 48h significantly reduces phosphorylation of Akt 23489999
human HCC cell lines Cell viability assay 0.005-1μM 48h IC50=1μM 23489999
786-0 Growth Inhibition Assay 1-20μM 72h IC50＜1μM 23479136
SK-HEP1 Growth Inhibition Assay 1-20μM 72h IC50＜1μM 23479136
primary B-CLL lymphocytes Kinase Assay IC50 for each primary cell line 24h inhibits p70S6K & 4E-BP1 expression 23238639
primary B-CLL lymphocytes Apoptosis Assay IC50 for each primary cell line 24h IC50＜3μM for all patients 23238639
MEC2 Cytotoxicity assay 0.2-20μM 72h IC50=0.7μM 23238639
EHEB Cytotoxicity assay 0.2-20μM 72h IC50=0.7μM 23238639
JVM2 Cytotoxicity assay 0.2-20μM 72h IC50=0.9μM 23238639
human NSCLC Kinase Assay 1μM 24h inhibits the Akt/mTOR signaling pathway at 3h after treatment 22781393
human NSCLC Growth Inhibition Assay 0.5-2μM 72h IC50=1μM 22781393
Y1 cell line Growth Inhibition Assay 0.1μM/1μM 24h inhibits 60％ cell viability in Myc-Sctr-transfected cells 22692904
MCF7-myr-Akt Growth Inhibition Assay GI50=299±68nM，LD50＞10,000nM 72h GI50=299±68nM，LD50＞10,000nM 22653967
PIK3CA-mutant MCF7 Kinase Assay IC50=114±3nM 72h IC50=114±3nM in reducing Akt phosphorylation levels 22653967
PIK3CA-mutant MCF7 Growth Inhibition Assay GI50=160±91nM，LD50=980±273nM 72h GI50=160±91nM，LD50=980±273nM 22653967
HT-29 and HCT-116 Caspase assay 5μM 24h induces caspase activity 22543857
HCT-116/HT-29/MKN-45 Apoptosis Assay 2μM 48h shift in G2 phase 22543857
gastric cancer cell lines Growth Inhibition Assay 0-10μM 72h IC50=2-5μM 22543857
colon cancer cell lines Growth Inhibition Assay 0-10μM 72h IC50=1μM 22543857
ARP-1 Apoptosis Assay 10μM 24h induces MM cell apoptosis through caspase activation 22207485
MM cell lines Growth Inhibition Assay 10μM 24h IC50 varies among different cell lines in time and dose dependence 22207485
U87 Apoptosis Assay 2μM 72h induces cell apoptosis and cleaved PARP and caspase-3 22065080
T-47D Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
SK-BR-3 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
UACC-732 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
BT-474 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC202 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
MCF7 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
MDA-MB-415 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
MDA-MB-453 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
ZR-75-1 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC38 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC1419 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
UACC-812 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC1187 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
KPL-1 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
SUM-225 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
EFM-192A Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
JIMT-1 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC1143 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC2218 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
MDA-MB-468 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
BT-20 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
MDA-MB-435 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
BT-549 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC1806 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
HCC1937 Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
Hs578T Growth Inhibition Assay 1 μM 5 d IC50<1 μM 24879796
Huh7 Function Assay 1 μM 1 h Inhibits phosphorylation of AKT at Ser474 25004403
BNL Function Assay 1 μM 1 h Inhibits phosphorylation of S6 25004403
BON-1 Growth Inhibition Assay 500 nM 10 d Inhibits cell growth 25026292
BON-1 Function Assay 500 nM 4 h Inhibits phosphorylation of AKT at Thr308 and Ser473 25026292
QGP-1 Function Assay 500 nM 4 h Inhibits phosphorylation of AKT at Thr308 and Ser473 25026292
HCT-15 Apotosis Assay 10 μM 48 h Induces apoptosis in HCT-15 cells harbouring PIK3CA hotspot mutation 25152245
HCT-116 Apotosis Assay 10 μM 48 h Induces apoptosis in HCT-116 cells harbouring PIK3CA hotspot mutation 25152245
NCI-H460 Apotosis Assay 10 μM 48 h Induces apoptosis in NCI-H460 cells harbouring PIK3CA hotspot mutation 25152245
SKOV-3 Apotosis Assay 10 μM 48 h Induces apoptosis in SKOV-3 cells harbouring PIK3CA hotspot mutation 25152245
BSY-1 Apotosis Assay 10 μM 48 h Induces apoptosis in BSY-1 cells harbouring PIK3CA hotspot mutation 25152245
MKN-1 Apotosis Assay 10 μM 48 h Induces apoptosis in MKN-1 cells harbouring PIK3CA hotspot mutation 25152245
NCI-H522 Apotosis Assay 10 μM 48 h Induces apoptosis 25152245
OVCAR-3 Apotosis Assay 10 μM 48 h Induces apoptosis 25152245
HBC-5 Apotosis Assay 10 μM 48 h Induces apoptosis 25152245
RXF-631L Apotosis Assay 10 μM 48 h Induces apoptosis 25152245
MKN-45 Apotosis Assay 10 μM 48 h Induces apoptosis 25152245
A549 Function Assay 500 nM 48 h Inhibits Akt activation 25937299
A549 Growth Inhibition Assay 1 μM 72 h Inhibits cell growth 25937299
H522 Growth Inhibition Assay 1 μM 72 h Inhibits cell growth 25937299
SKMES-1 Cytotoxic Assay 1 μM 72 h Induces cell death 26013318
HCT116 Function assay 10 uM 1 hr Inhibition of PI3K/Akt in human HCT116 cells assessed as Akt phosphorylation at 10 uM after 1 hr by Western blotting analysis 25765909
A2058 melanoma Cell cycle assay 5 uM 24 hrs Cell cycle arrest in human A2058 melanoma cells assessed as accumulation at SubG1 phase at 5 uM after 24 hrs by propidium iodide staining based FACS analysis 28829592
A2058 melanoma Cell cycle assay 5 uM 24 hrs Cell cycle arrest in human A2058 melanoma cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by propidium iodide staining based FACS analysis 28829592
SKOV3 Cell cycle assay 2 uM 24 hrs Cell cycle arrest in human SKOV3 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining based FACS analysis 28829592
SKOV3 Cell cycle assay 2 uM 24 hrs Cell cycle arrest in human SKOV3 cells assessed as accumulation at SubG1 phase at 2 uM after 24 hrs by propidium iodide staining based FACS analysis 28829592
HT-29 Cell cycle assay 0.111 to 3 uM 24 hrs Cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 0.111 to 3 uM after 24 hrs by propidium iodide staining based flow cytometry 30034607
LNCaP Function Assay 1 μM Suppresses p-AKT levels 25360799
LNCaP95 Function Assay 1 μM Suppresses p-AKT levels 25360799
H596 Function Assay 1 μM Impairs cell migration 26013318
HCC2450 Function Assay 1 μM Impairs cell invasion 26013318
SNU-719 Growth Inhibition Assay 72h IC50=3.037±0.032μM 22159814
SNU-620 Growth Inhibition Assay 72h IC50=2.939±0.001μM 22159814
SNU-484 Growth Inhibition Assay 72h IC50=1.728±0.045μM 22159814
SNU-16 Growth Inhibition Assay 72h IC50=1.573±0.001μM 22159814
SNU-638 Growth Inhibition Assay 72h IC50=2.282±0.053μM 22159814
SNU-5 Growth Inhibition Assay 72h IC50=1.351±0.091μM 22159814
SNU-216 Growth Inhibition Assay 72h IC50=2.692±0.082μM 22159814
AGS Growth Inhibition Assay 72h IC50=1.714±0.117μM 22159814
SNU-668 Growth Inhibition Assay 72h IC50=1.579±0.074μM 22159814
SNU-1 Growth Inhibition Assay 72h IC50=1.082±0.028μM 22159814
SNU-601 Growth Inhibition Assay 72h IC50=0.816±0.063μM 22159814
glioma cell lines Growth Inhibition Assay 72h IC50=1-2μM 22065080
MCF7 Cytotoxic Assay 72 h Cytotoxicity against human MCF7 cells expressing PI3Kalpha E545K mutant with GI50 of 0.000158 μM 24900266
DU145 Cytotoxic Assay 72 h Cytotoxicity against human DU145 cells expressing LKB1 mutant with GI50 of 0.000435 μM 24900266
A2780 Cytotoxic Assay 72 h Cytotoxicity against PTEN-deficient human A2780 cells with GI50 of 0.000635 μM 24900266
U87MG Cytotoxic Assay 72 h Cytotoxicity against PTEN-deficient human U87MG cells with GI50 of 0.000698 μM 24900266
A2780 Function Assay 1 h Inhibition of PI3K-mediated AKT Ser473 phosphorylation with EC50 of 0.055 μM 24900266
DU145 Function Assay 1 h Inhibition of PI3K-mediated AKT Ser473 phosphorylation in human DU145 cells harboring LKB1 mutation with EC50 of 0.073 μM 24900266
A2780 Function Assay 1 h Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human A2780 cells with EC50 of 0.074 μM 24900266
MCF7 Function Assay 1 h Inhibition of PI3Kalpha E545K mutant-mediated AKT Ser473 phosphorylation with EC50 of 0.1 μM 24900266
U87MG Function Assay 1 h Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human U87MG cells with EC50 of 0.13 μM 24900266
A2780 Growth Inhibition Assay 72 h EC50=0.52 μM 24900266
HCT116 Antiproliferative assay 72 hrs Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 0.48 μM. 25765909
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 1 μM. 25765909
U87MG Antiproliferative assay 72 hrs Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay, IC50 = 1.64 μM. 25765909
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 2.07 μM. 25765909
HeLa Antiproliferative assay 72 hrs Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay, IC50 = 4.34 μM. 25765909
MDA-MB-231 Cytotoxicity assay 72 hrs Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 1.88 μM. 29107429
PC3 Cytotoxicity assay 72 hrs Cytotoxicity against human PC3 cells after 72 hrs by MTT assay, IC50 = 5.34 μM. 29107429
T47D Cytotoxicity assay 72 hrs Cytotoxicity against human T47D cells after 72 hrs by MTT assay, IC50 = 6.92 μM. 29107429
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 11.05 μM. 29107429
Sf21 Function assay 1 hr Inhibition of recombinant human full-length N-terminal His6-tagged p110delta/recombinant human full length p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 1 hr by Alexa633 Tracer-based fluorescence polar, IC50 = 0.125 μM. 30034607
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells harboring PIK3CA E545K mutant after 72 hrs by MTT assay, IC50 = 0.206 μM. 30034607
Sf21 Function assay 1 hr Inhibition of recombinant human full-length N-terminal His6-tagged p110beta/recombinant human full length p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 1 hr by Alexa633 Tracer-based fluorescence polari, IC50 = 0.234 μM. 30034607
T47D Antiproliferative assay 72 hrs Antiproliferative activity against human T47D cells harboring PI3KCA H1047R mutant after 72 hrs by MTT assay, IC50 = 0.286 μM. 30034607
PC3 Function assay 2 hrs Inhibition of PI3K in human PC3 cells assessed as reduction in AKT phosphorylation at Ser473 measured after 2 hrs by fluorescence assay, IC50 = 0.365 μM. 30034607
A2058 Function assay 1 hr Inhibition of TORC2 in human A2058 cells assessed as decrease in PKB/Akt phosphorylation at Ser473 after 1 hr by Western blot analysis, IC50 = 0.416 μM. 30359003
A2058 Function assay 1 hr Inhibition of TORC1 in human A2058 cells assessed as decrease in S6 phosphorylation at Ser235/236 after 1 hr by Western blot analysis, IC50 = 0.553 μM. 30359003
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
insect Function assay Inhibition of recombinant human His-tagged p85alpha/p110alpha E545K mutant expressed in insect cells, IC50 = 0.011 μM. 30034607
insect Function assay Inhibition of recombinant human His-tagged p85alpha/p110alpha E542K mutant expressed in insect cells, IC50 = 0.029 μM. 30034607
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Targets
p110α [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 p110β [1]
(Cell-free assay)		 p110γ [1]
(Cell-free assay)		 Vps34 [1]
(Cell-free assay)		 もっとクリックする
52 nM 116 nM 166 nM 262 nM 2.4 μM
In Vitro
In vitro BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]
Kinase Assay PI3K biochemical assay (ATP depletion assay)
BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
細胞実験 細胞株 A2780 cells.
濃度 0-6.6 μM
反応時間 3 days.
実験の流れ A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
実験結果図 Methods Biomarkers 結果図 PMID
Western blot p-MET / MET p-STAT3 / STAT3 / p-ERK / ERK / p-S6 p-ERK / ERK / LC3 Nuclear NF-κB p65 / NF-κB p65 p-FOXO3a (S253) / FOXO3a p-AKT (T308) / p-AKT (S473) / AKT 29928341
Immunofluorescence FOXO3a 28036259
Growth inhibition assay Cell viability 26673665
In Vivo
In Vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]
動物実験 動物モデル U87MG and A2780 xenografts are established in female nu/nu mice.
投与量 ~60 mg/kg.
投与経路 Dosed orally daily (q.d.).
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Active not recruiting
Head and Neck Cancer
Adlai Nortye Biopharma Co. Ltd.
 December 12 2020 Phase 3
NCT02614508 Terminated
Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma
Emory University|Novartis
 January 2016 Phase 1
NCT01613677 Withdrawn
Treatment for Metastatic or Locally Advanced Cervical Cancer
Novartis Pharmaceuticals|Novartis
 November 2015 Phase 2

化学情報

分子量 410.39 化学式

C18H21F3N6O2
CAS No. 944396-07-0 SDF Download Buparlisib (BKM120) SDFをダウンロードする
Smiles C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
保管

In vitro
Batch:

DMSO : 82 mg/mL ( (199.8 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 25 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

mg/kg g μL 匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Buparlisib (BKM120)を買う | Buparlisib (BKM120) ic50 | Buparlisib (BKM120)供給者 | Buparlisib (BKM120)を購入する | Buparlisib (BKM120)費用 | Buparlisib (BKM120)生産者 | オーダーBuparlisib (BKM120) | Buparlisib (BKM120)化学構造 | Buparlisib (BKM120)分子量 | Buparlisib (BKM120)代理店